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Quo Vadis?Douglas L. Mann, MD, FACCW ith the successful launch of the inauguralissue of JACC: Basic to TranslationalScience on March 2, 2016, and the accom-
panying statement from the editors outlining the
rationale and goals for the journal (1), it is timely, if
not appropriate, for the second Editor’s Page to focus
on orienting our readers to the planned thematic con-
tent for JACC: Basic to Translational Science, and
more importantly, to provide a glimpse of where the
journal is heading in the future.
One of the major goals for JACC: Basic to Trans-
lational Science is to become a forum and learning
center for translational cardiovascular investigators
in academia and industry, patients and families
affected by heart disease, the National Heart, Lung,
and Blood Institute, and the U.S. Food and Drug
Administration (FDA). To this end, each issue of
JACC: Basic to Translational Science will have a State-
of-the-Art Review that summarizes research themes
that are both timely and cutting-edge, but that also
address novel research questions that bridge the gap
between basic science and clinical science. In the
current issue, the State-of-the-Art Review summa-
rizes the recent spate of “neutral” clinical trials that
have plagued device-based therapies that seek to
modulate the autonomic nervous system in heart
failure patients (2). The review concludes by discus-
sing several of the reasons why it has been so difﬁcult
to move neuromodulatory therapies from animal
models into successful phase II/III clinical trials.
JACC: Basic to Translational Science will also
feature a special content area referred to as the
“Translational Toolbox.” The papers in the toolbox
are intended to orient investigators to the various
regulatory issues that they will face when bringing
their ideas from the bench to the bedside, as well asFrom the American College of Cardiology, Washington, DC.inform investigators how to obtain funding for their
translational research efforts. For example, the ﬁrst
issue featured an excellent paper by Christopher
Colecchi and David Tancredi on how the Leducq
Foundation is funding translational cardiovascular
research through the creation of Broadview Ventures,
which promotes the development of technology for
the diagnosis and treatment of cardiovascular disease
and stroke through direct, equity-based investments
(3). Subsequent related features in the toolbox will
include papers on funding opportunities provided by
venture capitalists as well as the National Institutes
of Health. With respect to serving as a learning center
for translational investigators, the current issue of
JACC: Basic to Translational Science features the ﬁrst
of a 2-part series by Dr. Gail Van Norman that focuses
on understanding the basics of the FDA approval
process for drugs (4). This will be followed by a sec-
ond themed review paper on the FDA approval pro-
cess for devices. For basic investigators who are
unfamiliar with the regulatory approval process,
these 2 papers are a must read!
In an attempt to create a forum for discussions
dedicated to developing new cardiovascular thera-
pies, beginning with the current issue, JACC: Basic to
Translational Science will also feature a section enti-
tled “Translational Perspectives.” The vision for this
section is to create a mashup of Hyde Park sessions,
the more traditional Letter to the Editors section
(albeit longer), as well as au courant summaries of
trending issues in academia, industry, FDA, and
National Institutes of Health. As 1 example, in the
current issue, Bristow et al. (5) discuss issues related
to geographic inhomogeneity in patient recruitment
in the TOPCAT (Treatment of Preserved Cardiac
Function Heart Failure with an Aldosterone Antago-
nist) trial (6), and review how they may have nega-
tively inﬂuenced the primary endpoint of the trial.
More importantly, the authors provide guidance for
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191how to avoid similar types of problems in future
multinational trials.
JACC: BASIC TO TRANSLATIONAL SCIENCE—
QUO VADIS?
The editors are committed to creating a journal that
focuses on accelerating the translation of new scien-
tiﬁc discoveries into new therapies that improve
meaningful clinical outcomes for patients with car-
diovascular disease. Clearly this cannot happen in a
vacuum. Where JACC: Basic to Translational Science
goes in the future will depend on the needs and in-
terests of investigators in academia and industry,
patients, societies, and all of the governmentalregulatory agencies, all of whom we seek to engage
collaboratively in an effort to improve the health of
patients with heart and vascular disease. Please let us
know how we are doing and what you would like to
see in JACC: Basic to Translational Science. You can
share your thoughts about the thematic content
through social media (#JACCBTSQuoVadis) or by
e-mail (jaccbts@acc.org).
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